194 related articles for article (PubMed ID: 16913391)
1. Potential interactions of methylphenidate and atomoxetine with dextromethorphan.
Ciccone PE; Ramabadran K; Jessen LM
J Am Pharm Assoc (2003); 2006; 46(4):472-8. PubMed ID: 16913391
[TBL] [Abstract][Full Text] [Related]
2. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
3. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI
J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of dextromethorphan in human liver microsomes: a rapid HPCL assay to monitor cytochrome P450 2D6 activity.
Vielnascher E; Spatzenegger M; Mayrhofer A; Klinger P; Jäger W
Pharmazie; 1996 Aug; 51(8):586-8. PubMed ID: 8794469
[TBL] [Abstract][Full Text] [Related]
5. Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
Sangal RB; Owens J; Allen AJ; Sutton V; Schuh K; Kelsey D
Sleep; 2006 Dec; 29(12):1573-85. PubMed ID: 17252888
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1.
Schmider J; Greenblatt DJ; Fogelman SM; von Moltke LL; Shader RI
Biopharm Drug Dispos; 1997 Apr; 18(3):227-40. PubMed ID: 9113345
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
Brown JT; Bishop JR; Sangkuhl K; Nurmi EL; Mueller DJ; Dinh JC; Gaedigk A; Klein TE; Caudle KE; McCracken JT; de Leon J; Leeder JS
Clin Pharmacol Ther; 2019 Jul; 106(1):94-102. PubMed ID: 30801677
[TBL] [Abstract][Full Text] [Related]
8. Clinical pharmacokinetics of atomoxetine.
Sauer JM; Ring BJ; Witcher JW
Clin Pharmacokinet; 2005; 44(6):571-90. PubMed ID: 15910008
[TBL] [Abstract][Full Text] [Related]
9. Potent inhibition of cytochrome P-450 2D6-mediated dextromethorphan O-demethylation by terbinafine.
Abdel-Rahman SM; Marcucci K; Boge T; Gotschall RR; Kearns GL; Leeder JS
Drug Metab Dispos; 1999 Jul; 27(7):770-5. PubMed ID: 10383919
[TBL] [Abstract][Full Text] [Related]
10. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of atomoxetine serum levels by co-administration of paroxetine.
Paulzen M; Clement HW; Gründer G
Int J Neuropsychopharmacol; 2008 Mar; 11(2):289-91. PubMed ID: 18215333
[No Abstract] [Full Text] [Related]
12. O-demethylation of dextromethorphan using microbial cultures.
Prasanthi S; Vidyavathi M; Prasad KV; Krishna DR
Drug Metab Lett; 2009 Jan; 3(1):10-4. PubMed ID: 19356111
[TBL] [Abstract][Full Text] [Related]
13. Prefrontal grey and white matter neurometabolite changes after atomoxetine and methylphenidate in children with attention deficit/hyperactivity disorder: a (1)H magnetic resonance spectroscopy study.
Husarova V; Bittsansky M; Ondrejka I; Dobrota D
Psychiatry Res; 2014 Apr; 222(1-2):75-83. PubMed ID: 24679996
[TBL] [Abstract][Full Text] [Related]
14. Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: methylphenidate vs. atomoxetine treatments.
Harvey RC; Jordan CJ; Tassin DH; Moody KR; Dwoskin LP; Kantak KM
Behav Brain Res; 2013 May; 244():38-47. PubMed ID: 23376704
[TBL] [Abstract][Full Text] [Related]
15. Atomoxetine.
Unni JC
Indian Pediatr; 2006 Jul; 43(7):603-6. PubMed ID: 16891679
[No Abstract] [Full Text] [Related]
16. A novel incubation direct injection LC/MS/MS technique for in vitro drug metabolism screening studies involving the CYP 2D6 and the CYP 3A4 isozymes.
Bhoopathy S; Xin B; Unger SE; Karnes HT
J Pharm Biomed Anal; 2005 Apr; 37(4):739-49. PubMed ID: 15797796
[TBL] [Abstract][Full Text] [Related]
17. No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers.
Avenoso A; Facciolà G; Scordo MG; Spina E
Ther Drug Monit; 1999 Oct; 21(5):577-9. PubMed ID: 10519458
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
Stuhec M; Munda B; Svab V; Locatelli I
J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
[TBL] [Abstract][Full Text] [Related]
19. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?
Yu A; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1514-20. PubMed ID: 11602530
[TBL] [Abstract][Full Text] [Related]
20. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
